Impact Therap-b
Impact Therap-b (HKSE: 7630) is trading at HK$14.29, about ₹175 at today's HKD/INR rate, as of 29 Sep 2026, 11:59 PM ET, up 2.58% today. Indian residents can buy Impact Therap-b from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$13.70
Today's high
HK$15.11
52 week low
HK$10.31
52 week high
HK$47.98
7630 opened at HK$14.10, closed previously at HK$13.93, and has traded between HK$10.31 and HK$47.98 over the past 52 weeks.
About
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Key statistics
Avg. volume
2.10M
Market cap
HK$3.95B
P/E Ratio
-13.79
Price-to-sales ratio
29.34
Enterprise value
$1.57B
Free cash flow yield
-0.91%
Debt-to-equity ratio
0.01
Return on equity
30.08%
ROIC
-95.95%
Beta
0.23
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
$5.33M
Earnings per share
-$0.15
Free cash flow
-$13.57M
Net profit margin
-214.26%
Gross margin
87.17%
EBITDA
-$31.42M
Revenue growth
13.86%
How to buy Impact Therap-b from India
Indian residents can buy Impact Therap-b shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Impact Therap-b and place an order
Find Impact Therap-b by name or by its ticker, 7630, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Impact Therap-b trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Impact Therap-b position in HKD and INR. Impact Therap-b pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Impact Therap-b from India
Trading and taxes when buying Impact Therap-b from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneImpact Therap-b does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Impact Therap-b stock?
Yes. Impact Therap-b (7630) has been listed on the Hong Kong Stock Exchange since 2026, in the Drug Manufacturers - General industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Impact Therap-b share cost in rupees?
One Impact Therap-b share is HK$14.29 — about ₹175 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Impact Therap-b price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Impact Therap-b from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Impact Therap-b?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Impact Therap-b shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Impact Therap-b price. Paasa issues a capital-gains statement for your return.
Does Impact Therap-b pay a dividend?
No. Impact Therap-b does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Impact Therap-b from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Impact Therap-b a Hong Kong SAR China company, and does that change how it is taxed?
Impact Therap-b trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Impact Therap-b trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Impact Therap-b shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Impact Therap-b holding, its cost and its closing value.
How do I sell Impact Therap-b and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.